Intra-Cellular Therapies Company Profile (NASDAQ:ITCI)

About Intra-Cellular Therapies

Intra-Cellular Therapies logoIntra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company's pipeline includes approximately two product candidates in clinical development and two product candidates in advanced pre-clinical testing. Its platform includes ITI-007 platform and phosphodiesterase (PDE) Inhibitor Platform. It is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, behavioral disturbances associated with dementia, autism and other CNS diseases. Its ITI-007 platform also includes long acting injectable (LAI) program, and IC200131 program for mood and other disorders. Its PDE Inhibitor Platform includes PDE1 program and PDE2 and PDE9 programs.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ITCI
  • CUSIP:
Key Metrics:
  • Previous Close: $13.27
  • 50 Day Moving Average: $14.40
  • 200 Day Moving Average: $22.35
  • 52-Week Range: $10.80 - $45.20
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.05
  • P/E Growth: 0.00
  • Market Cap: $574.17M
  • Outstanding Shares: 43,268,000
  • Beta: 1.21
Profitability:
  • Return on Equity: -26.85%
  • Return on Assets: -24.31%
Debt:
  • Current Ratio: 3.85%
  • Quick Ratio: 3.85%
Additional Links:
Companies Related to Intra-Cellular Therapies:

Analyst Ratings

Consensus Ratings for Intra-Cellular Therapies (NASDAQ:ITCI) (?)
Ratings Breakdown: 2 Hold Ratings, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.78)
Consensus Price Target: $41.11 (209.80% upside)

Analysts' Ratings History for Intra-Cellular Therapies (NASDAQ:ITCI)
Show:
DateFirmActionRatingPrice TargetDetails
12/22/2016BTIG ResearchInitiated CoverageBuy$44.00View Rating Details
12/16/2016Cantor FitzgeraldInitiated CoverageOverweight$32.00View Rating Details
11/9/2016Piper Jaffray CompaniesReiterated RatingOverweight$22.00View Rating Details
9/30/2016RBC Capital MarketsReiterated RatingOutperform$74.00 -> $49.00View Rating Details
9/30/2016Leerink SwannReiterated RatingOutperform$95.00 -> $29.00View Rating Details
9/29/2016JMP SecuritiesDowngradeOutperform -> Market PerformView Rating Details
9/29/2016Royal Bank Of CanadaLower Price TargetOutperform$74.00 -> $49.00View Rating Details
9/29/2016SunTrust Banks, Inc.DowngradeBuy -> Neutral$60.00 -> $15.00View Rating Details
8/5/2016Cowen and CompanyReiterated RatingBuy$75.00View Rating Details
9/29/2015GuggenheimBoost Price TargetBuy$95.00 -> $104.00View Rating Details
9/17/2015Ladenburg Thalmann Financial ServicesReiterated RatingBuy$54.00 -> $75.00View Rating Details
(Data available from 2/20/2015 forward)

Earnings

Earnings History for Intra-Cellular Therapies (NASDAQ:ITCI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/23/2017($0.77)N/AView Earnings Details
11/9/2016Q316($0.84)($0.70)$0.04 million$4.36 millionViewListenView Earnings Details
8/4/2016Q216($0.79)($0.71)$0.02 million$0.23 millionViewN/AView Earnings Details
4/28/2016Q116($0.78)($0.64)$0.02 millionViewListenView Earnings Details
2/25/2016Q415($0.87)($0.67)$0.05 million$30.66 millionViewListenView Earnings Details
11/5/2015Q315($0.66)($0.91)ViewN/AView Earnings Details
8/5/2015Q215($0.72)($0.61)$40.00 million$57.40 millionViewN/AView Earnings Details
4/30/2015Q1($0.68)($0.72)ViewN/AView Earnings Details
3/12/2015($0.49)($0.52)ViewN/AView Earnings Details
11/3/2014Q314($0.28)($0.22)ViewN/AView Earnings Details
8/12/2014Q214($0.23)($0.15)ViewN/AView Earnings Details
5/8/2014($0.23)($0.17)ViewN/AView Earnings Details
3/26/2014($0.41)($0.36)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Intra-Cellular Therapies (NASDAQ:ITCI)
Current Year EPS Consensus Estimate: $-2.82 EPS
Next Year EPS Consensus Estimate: $-3.28 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.74)($0.63)($0.69)
Q2 20162($0.79)($0.65)($0.72)
Q3 20163($0.82)($0.66)($0.71)
Q4 20162($0.78)($0.69)($0.74)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Intra-Cellular Therapies (NASDAQ:ITCI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Intra-Cellular Therapies (NASDAQ:ITCI)
Insider Ownership Percentage: 19.80%
Institutional Ownership Percentage: 64.02%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/5/2017Lawrence J HinelineVPSell1,918$16.58$31,800.44View SEC Filing  
1/5/2017Michael HalsteadSVPSell1,601$16.55$26,496.55View SEC Filing  
1/5/2017Sharon MatesChairmanSell4,081$16.55$67,540.55View SEC Filing  
12/15/2016Kimberly E VanoverSVPSell9,375$15.23$142,781.25View SEC Filing  
12/7/2016Alafi Capital Co LlcMajor ShareholderBuy65,000$16.27$1,057,550.00View SEC Filing  
11/14/2016Christopher D AlafiDirectorBuy34,000$14.50$493,000.00View SEC Filing  
2/29/2016Christopher D AlafiDirectorBuy100,000$29.70$2,970,000.00View SEC Filing  
12/15/2015Lawrence J. HinelineCFOSell45,000$51.45$2,315,250.00View SEC Filing  
12/11/2015Sharon MatesCEOSell51,500$53.87$2,774,305.00View SEC Filing  
12/8/2015Joel S MarcusDirectorSell92,700$54.47$5,049,369.00View SEC Filing  
11/24/2015Lawrence J HinelineCFOSell5,000$55.00$275,000.00View SEC Filing  
6/8/2015Lawrence P WennogleVPSell25,000$26.84$671,000.00View SEC Filing  
3/11/2015Christopher D AlafiDirectorBuy625,000$24.00$15,000,000.00View SEC Filing  
12/9/2014Lawrence J HinelineCFOSell22,500$16.71$375,975.00View SEC Filing  
12/1/2014Moshe AlafiMajor ShareholderBuy1,422$14.75$20,974.50View SEC Filing  
11/28/2014Christopher D AlafiDirectorBuy35,000$14.75$516,250.00View SEC Filing  
11/19/2014Alafi Capital Co LlcMajor ShareholderBuy1,034$14.25$14,734.50View SEC Filing  
11/18/2014Alafi Capital Co LlcMajor ShareholderBuy3,664$14.26$52,248.64View SEC Filing  
11/13/2014Alafi Capital Co LlcMajor ShareholderBuy12,200$15.34$187,148.00View SEC Filing  
11/6/2014Michael HalsteadSVPBuy20,000$15.38$307,600.00View SEC Filing  
10/15/2014Lawrence P WennogleVPSell3,604$15.00$54,060.00View SEC Filing  
10/13/2014Lawrence P WennogleVPSell1,600$15.00$24,000.00View SEC Filing  
10/8/2014Lawrence P WennogleVPSell4,745$15.00$71,175.00View SEC Filing  
10/6/2014Lawrence P WennogleVPSell16,499$15.00$247,485.00View SEC Filing  
9/15/2014Lawrence P WennogleVPSell5,000$15.00$75,000.00View SEC Filing  
9/8/2014Lawrence J HinelineCFOSell300$15.00$4,500.00View SEC Filing  
5/22/2014Lawrence P WennogleVPSell6,000$15.00$90,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Intra-Cellular Therapies (NASDAQ:ITCI)
DateHeadline
News IconIs The Sell-Side Predicting That Intra-Cellular Therapies Inc. (NASDAQ:ITCI) Will Move Higher? - Winfield Review (NASDAQ:ITCI)
winfieldreview.com - February 16 at 4:52 PM
News IconAre Analysts Optimistic About Where Intra-Cellular Therapies Inc. (NASDAQ:ITCI) is Heading? - Winfield Review (NASDAQ:ITCI)
winfieldreview.com - February 15 at 9:09 PM
nasdaq.com logoNoteworthy Monday Option Activity: SMG, ITCI, SBUX - Nasdaq (NASDAQ:ITCI)
www.nasdaq.com - January 31 at 2:36 AM
marketnewsvideo.com logoNoteworthy Monday Option Activity: SMG, ITCI, SBUX (NASDAQ:ITCI)
www.marketnewsvideo.com - January 30 at 4:34 PM
News IconIntra-Cellular Therapies Inc. (NASDAQ:ITCI) Projected EPS At $-0.77 - Stock Observer (NASDAQ:ITCI)
www.thestockobserver.com - January 29 at 6:18 PM
News IconPrice Index Watch on Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - The Tribune (NASDAQ:ITCI)
lakecitytribune.com - January 26 at 5:33 AM
realistinvestor.com logoEPS Projection Of Intra-Cellular Therapies Inc. (NASDAQ:ITCI) At $-0.95 - RealistInvestor.com (NASDAQ:ITCI)
www.realistinvestor.com - January 26 at 5:33 AM
investornewswire.com logoIntra-Cellular Therapies Inc. (NASDAQ:ITCI) Records An Impact Score Of 100 - Investor Newswire (NASDAQ:ITCI)
www.investornewswire.com - January 22 at 5:50 PM
capitalcube.com logoIntra-Cellular Therapies, Inc. – Value Analysis (NASDAQ:ITCI) : January 19, 2017 (NASDAQ:ITCI)
www.capitalcube.com - January 19 at 7:47 PM
capitalcube.com logoIntra-Cellular Therapies, Inc. breached its 50 day moving average in a Bearish Manner : ITCI-US : January 18, 2017 (NASDAQ:ITCI)
www.capitalcube.com - January 18 at 6:30 PM
News IconAre There Catalysts to Propel This Stock Forward: Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - Prospect Journal (NASDAQ:ITCI)
prospectjournal.com - January 17 at 1:00 PM
News IconIntra-Cellular Therapies Inc. (NASDAQ:ITCI) Projected to Achieve EPS Of $-0.77 - Stock Observer (NASDAQ:ITCI)
www.thestockobserver.com - January 16 at 5:59 PM
News IconWill The Needle Move For Intra-Cellular Therapies Inc. (NASDAQ:ITCI) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:ITCI)
wsbeacon.com - January 16 at 5:59 PM
finance.yahoo.com logoTESARO Varubi IV Gets Complete Response Letter in the U.S. (NASDAQ:ITCI)
finance.yahoo.com - January 13 at 7:16 PM
realistinvestor.com logoIntra-Cellular Therapies Inc. (NASDAQ:ITCI) EPS Estimate At $-0.95 - RealistInvestor.com (NASDAQ:ITCI)
www.realistinvestor.com - January 11 at 6:38 PM
News IconStock Getting Tripped Up In Session: Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - Wall Street Beacon (NASDAQ:ITCI)
wsbeacon.com - January 11 at 6:38 PM
News IconStock Reaching Most Volatile List Today: Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - Wall Street Beacon (NASDAQ:ITCI)
wsbeacon.com - January 11 at 6:38 PM
News IconSVP and General Counsel of Intra-Cellular Therapies Inc (NASDAQ:ITCI), Halstead Michael, sells 1,601 shares worth $26,497 (NASDAQ:ITCI)
empowerednews.net - January 10 at 11:53 PM
News IconProjected EPS Of Intra-Cellular Therapies Inc. (NASDAQ:ITCI) At $-0.77 - Stock Observer (NASDAQ:ITCI)
www.thestockobserver.com - January 10 at 6:53 PM
News IconStock ABR Intra-Cellular Therapies Inc. (NASDAQ:ITCI) At 1.71 - Stock Observer (NASDAQ:ITCI)
www.thestockobserver.com - January 10 at 6:53 PM
biz.yahoo.com logoINTRA-CELLULAR THERAPIES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement (NASDAQ:ITCI)
biz.yahoo.com - January 10 at 6:53 PM
News IconVP of Finance CFO of Intra-Cellular Therapies Inc (NASDAQ:ITCI), Hineline Lawrence J., sells 1,918 shares worth $31,800 (NASDAQ:ITCI)
empowerednews.net - January 9 at 9:14 PM
News IconInsider Filing On Watch: Intra-Cellular Therapies Inc (NASDAQ:ITCI)’s Insider Michael Halstead Unloaded 1,601 Shares (NASDAQ:ITCI)
www.whatsonthorold.com - January 9 at 9:14 PM
News IconNoteworthy Friday Option Activity: ITCI, ACOR, SC (NASDAQ:ITCI)
www.stockoptionschannel.com - January 6 at 6:41 PM
finance.yahoo.com logoIntra-Cellular Therapies to Present at the 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:ITCI)
finance.yahoo.com - January 4 at 6:51 PM
marketexclusive.com logoAnalyst Activity – BTIG Research Initiates Coverage On Intra-Cellular Therapies (NASDAQ:ITCI) With a Buy (NASDAQ:ITCI)
marketexclusive.com - December 23 at 6:15 PM
News IconRating Alert: Intra-Cellular Therapies (NASDAQ:ITCI) Is A Stock Cantor Fitzgerald Is Interested In (NASDAQ:ITCI)
www.whatsonthorold.com - December 19 at 11:25 AM
marketexclusive.com logoAnalyst Activity – Cantor Fitzgerald Initiates Coverage On Intra-Cellular Therapies (NASDAQ:ITCI) With a Overweight (NASDAQ:ITCI)
marketexclusive.com - December 16 at 6:34 PM
finance.yahoo.com logoCoverage initiated on Intra-Cellular Therapies by Cantor Fitzgerald (NASDAQ:ITCI)
finance.yahoo.com - December 16 at 6:34 PM
finance.yahoo.com logoWhy Intra-Cellular Therapies (ITCI) Could Be Positioned for a Surge (NASDAQ:ITCI)
finance.yahoo.com - December 12 at 10:49 AM
News IconInsider Move to Note: Is ITI Inc (NASDAQ:ITCI) Stock a Buy after Moshe Alafi’s Insider Purchase? (NASDAQ:ITCI)
www.whatsonthorold.com - December 7 at 11:06 PM
News IconInsider Analysis: The director of ITI Inc (NASDAQ:ITCI), Christopher Alafi Acquired 65,000 Shares (NASDAQ:ITCI)
www.whatsonthorold.com - December 7 at 6:06 PM
News IconIntra-Cellular Therapies Inc. (NASDAQ:ITCI) Stock ABR At 1.71 - Stock Observer (NASDAQ:ITCI)
www.thestockobserver.com - December 7 at 1:20 AM
News IconFree Cash Flow Score in Focus for Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - The Business Journal (NASDAQ:ITCI)
belmontbusinessjournal.com - December 6 at 3:17 PM
News IconStock Volatility Review for Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - The Business Journal (NASDAQ:ITCI)
belmontbusinessjournal.com - December 3 at 5:26 PM
News IconChecking the Metrics on Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - Marion Business Daily (NASDAQ:ITCI)
marionbusinessdaily.com - December 2 at 5:47 PM
insidermonkey.com logo10 Stocks Insiders and Hedge Funds Are Crazy About (part 1) (NASDAQ:ITCI)
www.insidermonkey.com - December 2 at 5:47 PM
finance.yahoo.com logoIntra-Cellular Therapies to Present at the 55th Annual Meeting of the American College of Neuropsychopharmacology (NASDAQ:ITCI)
finance.yahoo.com - December 1 at 10:13 AM
finance.yahoo.com logoWill Intra-Cellular Therapies (ITCI) Crush Estimates at Its Next Earnings Report? (NASDAQ:ITCI)
finance.yahoo.com - December 1 at 10:13 AM
insidermonkey.com logoIntra-Cellular Therapies Inc (ITCI): Hedge Fund Sentiment Takes A Turn for the Worse - Insider Monkey (blog) (NASDAQ:ITCI)
www.insidermonkey.com - November 30 at 6:07 PM
News IconIntra-Cellular Therapies Inc (ITCI): Hedge Fund Sentiment Takes A Turn for the Worse (NASDAQ:ITCI)
feedproxy.google.com - November 28 at 6:21 PM
stocksdaily.net logoIntra-Cellular Therapies Inc. (NASDAQ:ITCI) EPS Target Set At $-0.77 - Stocks Daily (NASDAQ:ITCI)
www.stocksdaily.net - November 25 at 5:42 PM
globenewswire.com logoIntra-Cellular Therapies to Participate at Upcoming Investor Conferences - GlobeNewswire (press release) (NASDAQ:ITCI)
globenewswire.com - November 24 at 8:49 AM
News IconIntra-Cellular Therapies to Participate at Upcoming Investor Conferences - EconoTimes (NASDAQ:ITCI)
www.econotimes.com - November 23 at 8:33 AM
publicnow.com logoIntra-Cellular Therapies to Participate at Upcoming Investor Conferences (NASDAQ:ITCI)
www.publicnow.com - November 23 at 8:33 AM
News IconIntra-Cellular Therapies Inc. (NASDAQ:ITCI) Projected to Report EPS Of $-0.77 - Stock Observer (NASDAQ:ITCI)
www.thestockobserver.com - November 21 at 10:49 AM
News IconStock in Focus: Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - Marion Business Daily (NASDAQ:ITCI)
marionbusinessdaily.com - November 19 at 8:16 AM
News IconInsider Worth Mentioning: Intra-Cellular Therapies Inc (NASDAQ:ITCI)’s Insider Capital Alafi Purchased 34,000 Shares of the Company (NASDAQ:ITCI)
www.whatsonthorold.com - November 18 at 5:16 PM
finance.yahoo.com logoINTRA-CELLULAR THERAPIES, INC. Financials (NASDAQ:ITCI)
finance.yahoo.com - November 17 at 5:19 PM
News IconInvestors are Watching Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - The Business Journal (NASDAQ:ITCI)
belmontbusinessjournal.com - November 16 at 5:57 PM

Social

What is Intra-Cellular Therapies' stock symbol?

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

Where is Intra-Cellular Therapies' stock going? Where will Intra-Cellular Therapies' stock price be in 2017?

9 brokers have issued 1 year price targets for Intra-Cellular Therapies' stock. Their forecasts range from $15.00 to $75.00. On average, they anticipate Intra-Cellular Therapies' stock price to reach $41.11 in the next year.

When will Intra-Cellular Therapies announce their earnings?

Intra-Cellular Therapies is scheduled to release their next quarterly earnings announcement on Thursday, February, 23rd 2017.

Who owns Intra-Cellular Therapies stock?

Intra-Cellular Therapies' stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (15.00%), State Street Corp (2.25%), Bogle Investment Management L P DE (1.05%), Sarissa Capital Management LP (0.83%), Clough Capital Partners L P (0.81%) and Frontier Capital Management Co. LLC (0.23%). Company insiders that own Intra-Cellular Therapies stock include Alafi Capital Co Llc, Christopher D Alafi, Joel S Marcus, Kimberly E Vanover, Lawrence J Hineline, Lawrence P Wennogle, Michael Halstead and Sharon Mates.

Who sold Intra-Cellular Therapies stock? Who is selling Intra-Cellular Therapies stock?

Intra-Cellular Therapies' stock was sold by a variety of institutional investors in the last quarter, including Oxford Asset Management and Frontier Capital Management Co. LLC. Company insiders that have sold Intra-Cellular Therapies stock in the last year include Kimberly E Vanover, Lawrence J Hineline, Michael Halstead and Sharon Mates.

Who bought Intra-Cellular Therapies stock? Who is buying Intra-Cellular Therapies stock?

Intra-Cellular Therapies' stock was purchased by a variety of institutional investors in the last quarter, including Bogle Investment Management L P DE, Sarissa Capital Management LP, Clough Capital Partners L P, State Street Corp, A.R.T. Advisors LLC, Dimensional Fund Advisors LP, Russell Investments Group Ltd. and Royce & Associates LP. Company insiders that have bought Intra-Cellular Therapies stock in the last two years include Alafi Capital Co Llc and Christopher D Alafi.

How do I buy Intra-Cellular Therapies stock?

Shares of Intra-Cellular Therapies can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Intra-Cellular Therapies stock cost?

One share of Intra-Cellular Therapies stock can currently be purchased for approximately $13.27.

Intra-Cellular Therapies (NASDAQ:ITCI) Chart for Monday, February, 20, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Earnings History Chart

Earnings by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Dividend History Chart

Dividend Payments by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Last Updated on 2/20/2017 by MarketBeat.com Staff